JPWO2021117861A1 - - Google Patents

Info

Publication number
JPWO2021117861A1
JPWO2021117861A1 JP2021564057A JP2021564057A JPWO2021117861A1 JP WO2021117861 A1 JPWO2021117861 A1 JP WO2021117861A1 JP 2021564057 A JP2021564057 A JP 2021564057A JP 2021564057 A JP2021564057 A JP 2021564057A JP WO2021117861 A1 JPWO2021117861 A1 JP WO2021117861A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021564057A
Other languages
Japanese (ja)
Other versions
JP7093473B2 (en
JPWO2021117861A5 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021117861A1 publication Critical patent/JPWO2021117861A1/ja
Publication of JPWO2021117861A5 publication Critical patent/JPWO2021117861A5/ja
Priority to JP2022097803A priority Critical patent/JP2022123069A/en
Application granted granted Critical
Publication of JP7093473B2 publication Critical patent/JP7093473B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021564057A 2019-12-13 2020-12-11 Small tablets with excellent manufacturability and elution Active JP7093473B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022097803A JP2022123069A (en) 2019-12-13 2022-06-17 Small-sized tablet having excellent producibility and leachability

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019225718 2019-12-13
JP2019225718 2019-12-13
PCT/JP2020/046253 WO2021117861A1 (en) 2019-12-13 2020-12-11 Small-sized tablet having excellent producibility and elution properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022097803A Division JP2022123069A (en) 2019-12-13 2022-06-17 Small-sized tablet having excellent producibility and leachability

Publications (3)

Publication Number Publication Date
JPWO2021117861A1 true JPWO2021117861A1 (en) 2021-06-17
JPWO2021117861A5 JPWO2021117861A5 (en) 2022-06-02
JP7093473B2 JP7093473B2 (en) 2022-06-29

Family

ID=76330003

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564057A Active JP7093473B2 (en) 2019-12-13 2020-12-11 Small tablets with excellent manufacturability and elution
JP2022097803A Pending JP2022123069A (en) 2019-12-13 2022-06-17 Small-sized tablet having excellent producibility and leachability

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022097803A Pending JP2022123069A (en) 2019-12-13 2022-06-17 Small-sized tablet having excellent producibility and leachability

Country Status (5)

Country Link
JP (2) JP7093473B2 (en)
KR (1) KR20220113942A (en)
CN (1) CN114945370A (en)
TW (1) TW202135826A (en)
WO (1) WO2021117861A1 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523141A (en) * 2006-01-13 2009-06-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of triazine derivative and HMG-CoA reductase inhibitor
JP2009523139A (en) * 2006-01-13 2009-06-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of triazine derivative and insulin secretagogue
JP2012511521A (en) * 2008-12-12 2012-05-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of insulin and triazine and its use for treating diabetes
WO2014038593A2 (en) * 2012-09-05 2014-03-13 テイカ製薬株式会社 Granulated material for tablet that rapidly disintegrates in mouth
JP2017141289A (en) * 2012-01-06 2017-08-17 エルセリクス セラピューティクス インコーポレイテッド Biguanide composition and method for treating metabolic disorder
WO2017170858A1 (en) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 Oral preparation having exceptional elutability
JP2018154586A (en) * 2017-03-17 2018-10-04 ライオン株式会社 tablet

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI436768B (en) 2010-06-09 2014-05-11 Poxel Treatment of type 2 diabetes
CN112218623A (en) * 2018-06-14 2021-01-12 博希尔公司 Film-coated tablet comprising triazine derivative for treating diabetes

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523141A (en) * 2006-01-13 2009-06-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of triazine derivative and HMG-CoA reductase inhibitor
JP2009523139A (en) * 2006-01-13 2009-06-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of triazine derivative and insulin secretagogue
JP2012511521A (en) * 2008-12-12 2012-05-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of insulin and triazine and its use for treating diabetes
JP2017141289A (en) * 2012-01-06 2017-08-17 エルセリクス セラピューティクス インコーポレイテッド Biguanide composition and method for treating metabolic disorder
WO2014038593A2 (en) * 2012-09-05 2014-03-13 テイカ製薬株式会社 Granulated material for tablet that rapidly disintegrates in mouth
WO2017170858A1 (en) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 Oral preparation having exceptional elutability
JP2018154586A (en) * 2017-03-17 2018-10-04 ライオン株式会社 tablet

Also Published As

Publication number Publication date
JP7093473B2 (en) 2022-06-29
JP2022123069A (en) 2022-08-23
KR20220113942A (en) 2022-08-17
CN114945370A (en) 2022-08-26
TW202135826A (en) 2021-10-01
WO2021117861A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
BR112019017762A2 (en)
BR112021017339A2 (en)
BR112021017939A2 (en)
BR112019016141A2 (en)
AU2020104490A4 (en)
BR112021017738A2 (en)
BR112019016142A2 (en)
BR112019016138A2 (en)
BR112021017234A2 (en)
BR112021017355A2 (en)
BR112021017173A2 (en)
BR112021017083A2 (en)
BR112021017637A2 (en)
BR112021008711A2 (en)
BR112021012348A2 (en)
BR112021013128A2 (en)
BR112021017732A2 (en)
BR112021017949A2 (en)
BR112021017983A2 (en)
BR112021017703A2 (en)
BR112021016996A2 (en)
BR112021017010A2 (en)
AT524962A5 (en)
BR112019016136A2 (en)
BR112021016821A2 (en)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220405

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220617

R150 Certificate of patent or registration of utility model

Ref document number: 7093473

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150